Online Supplement

Persistent cardiac organ damage in surgically and medically treated primary aldosteronism

Arleen Aune[1,2,] Eva Gerdts[1,2,] Marina Kokorina[2,] Ester Kringeland[1,2,] Helga Midtbø[2,] Kristian Løvås[3,] Marianne A. Grytaas[3]

[1]Department of Clinical Science, University of Bergen, Bergen, Norway; [2]Department of Heart Disease, Haukeland University Hospital, Bergen, Norway; [3]Department of Medicine, Haukeland University Hospital, Bergen, Norway

Table S1. Factors associated with cardiac organ damage in 84 patients treated surgically or medically for primary aldosteronism. Univariable logistic regression analysis.

	Persistent LV hypertrophy		**Perisistently low MWS**		**Persistently low GLS**		**Persistenly enlarged LA**	
	OR(95% CI)	**p-value**	**OR(95% CI)**	**p**	**OR(95% CI)**	**p-value**	**OR(95% CI)**	**p**
Medical treatment group	7.32(2.22-24.2)	0.001	2.53(0.86-7.47)	0.093	0.93(0.32-2.69)	NS	2.24(0.62-8.14)	NS
Age (years)	1.06(1.01-1.12)	0.018	1.09(1.02-1.15)	0.005	1.04(0.99-1.09)	NS	1.03(0.97-1.09)	NS
Male sex	0.66(0.21-2.06)	NS	0.65(0.19-2.20)	NS	0.69(0.20-2.40)	NS	0.83(0.20-3.40)	NS
Duration of hypertension (years)	1.09 (1.03-1.15)	0.005	1.09(1.03-1.16)	0.005	1.03(0.97-1.09)	NS	1.03(0.97-1.10)	NS
Systolic BP at baseline (mmHg)	1.03 (1.00-1.06)	0.027	1.01(0.81-1.27)	NS	1.00(0.97-1.03)	NS	1.02(0.98-1.05)	NS
BP medication at baseline (DDD)	1.27 (1.03-1.57)	0.029	1.01(0.81-1.26)	NS	1.03(0.82-1.31)	NS	0.96(0.73-1.27)	NS
BMI (kg/m^2)	1.16 (1.04-1.29)	0.006	1.02(0.93-1.13)	NS	1.09(0.97-1.21)	NS	1.10(0.97-1.25)	NS
Obesity	2.24(0.84-5.97)	NS	0.80(0.28-2.24)	NS	2.83(0.93-8.60)	0.066	7.50(1.53-36.84)	0.013
Diabetes mellitus	11.05(2.59-47.08)	0.001	1.31(0.31-5.53)	NS	2.43(0.60-9.81)	NS	1.51(0.28-8.12)	NS
HbA_{1c} (%)	2.97(1.38-6.40)	0.005	1.24(0.63-2.45)	NS	2.37(1.12-5.02)	0.024	1.11(0.49-2.48)	NS
Atrial fibrillation	0.30(0.36-2.55)	NS	1.84(0.41-8.20)	NS	2.12(0.45-9.91)	NS	4.33(0.88-21.29)	0.071
eGFR (ml/min/1.73m^2)	0.98(0.96-1.00)	0.063	0.96(0.94-0.99)	0.003	1.00(0.97-1.02)	NS	0.97(0.94-1.00)	0.027
PAC pmol/L (per 10)	1.00(1.00-1.01)	NS	1.01(1.00-1.01)	0.027	1.01(0.99-1.03)	NS	1.00(1.00-1.01)	NS
Post-SIT PAC pmol/L (per 10)	1.00(0.99-1.02)	NS	1.00(0.98-1.02)	NS	1.01(0.99-1.03)	NS	1.00(0.98-1.02)	NS
Hypokalemia	1.47(0.43-5.02)	NS	0.40(0.13-2.22)	NS	0.71(0.23-2.15)	NS	0.75(0.21-2.73)	NS
Systolic BP at follow-up (mmHg)	1.03(1.00-1.06)	0.094	1.01(0.98-1.04)	NS	1.02(0.99-1.06)	NS	1.01(0.98-1.05)	NS
Pulspressure at follow-up	1.06(1.02-1.10)	0.004	1.02(0.98-1.05)	NS	1.01(0.98-1.05)	NS	104(1.00-1.08)	0.080
Controlled BP at follow-up	1.16(0.33-4.06)	NS	5.4(0.67-43.87)	NS	1.18(0.29-4.76)	NS	0.68(0.16-0.29)	NS
Delta systolic BP (mmHg)	1.01(0.98-1.03)	NS	0.99(0.96-1.02)	NS	0.89(0.95-1.01)	NS	1.00(0.97-1.04)	NS
Persistently low p-renin	4.90(1.37-17.54)	0.015	4.54(1.26-16.34)	0.021	1.46(0.34-6.34)	NS	2.26(0.51-9.95)	NS
Persistent LVH at follow-up	NA	NA	3.28(1.12-9.63)	0.031	3.07(1.00-9.46)	0.051	3.38(0.95-11.92)	0.059
E/e' at follow-up	1.25(1.04-1.50)	0.016	1.10(0.93-1.31)	NS	1.01(0.83-1.23)	NS	1.22(1.01-1.48)	0.046

OR, odds ratio; CI, confidence interval; LV, left ventricle; MWS, midwall shortening; LA, left atrium; GLS, global longitudinal strain; BP, blood pressure; DDD, defined daily dose; BMI, body mass index; HbA_{1c}, hemoglobin A_{1c}; eGFR, estimated glomerular filtration rate; PAC, plasma aldosterone concentration; post-SIT, post saline infusion testing¸LVH; LV hypertrophy